MediciNova appoints Kousuke Nakata to board
This article was originally published in Scrip
Biopharmaceutical company MediciNova has appointed Kousuke Nakata to its board of directors. Mr Nakata is licensing manager of Kissei Pharmaceutical, where he has been employed since 1997. Kissei is MediciNova's biggest shareholder.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.